Real-world Outcomes Among Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Initiating Teclistamab (Tec) at a Large Community Oncology Center in the US

First Author: Yair Levy
Session Information: 9/17/2025-9/20/2025

Download Poster

Poster Transcript

Introduction:

• Teclistamab was the first-in-class B-cell maturation antigen (BCMA) x CD3 bispecific antibody approved for the treatment of relapsed/refractory multiple myeloma (RRMM) that demonstrated an overall response rate (ORR) of 63%, after a median follow-up of 30.4 months in the MajesTEC-1 trial¹
• Most U.S. patients with multiple myeloma (MM) are treated in community oncology clinics, where practice patterns may differ from academic centers²
• However, real-world data on teclistamab has been largely reported from academic centers with step-up dosing (SUD) conducted primarily in inpatient settings^3-6

Objective

• To describe the clinical characteristics, SUD patterns, safety, and effectiveness of teclistamab in patients with RRMM treated at Texas Oncology, a large U.S. community oncology practice network

Methods:

Study design and data source

• This retrospective, observational study used patient charts and electronic medical record data for adult patients with RRMM treated with teclistamab at Texas Oncology’s practices

Study population

• Adult patients with ≥1 record of MM diagnosis based on the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code (C90.0x) and ≥1 record for teclistamab between 10/26/2022 and 12/31/2024 were included
• Patients who received teclistamab in a clinical trial were excluded
• The date of the first observed diagnosis was considered the initial MM diagnosis date, and the date of Teclistamab initiation was defined as the index date
• Eligible patients were followed from the index date to the last activity, death, or data cutoff (12/31/2024)
• Tec-1 eligible subgroup: patients eligible for teclistamab per US Prescribing Information (USPI), defined as meeting the following criteria:
  • Prior triple class exposed (TCE), including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody
  • Four prior lines of therapy prior to teclistamab initiation
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • No exposure to anti-BCMA therapy (ciltacabtagene autoleucel, idecabtagene vicleucel, elranatamab, or belantamab mafodotin) prior to teclistamab initiation

Data analysis

• All variables were summarized descriptively for all patients (the overall cohort) and for the Tec-1 eligible subgroup
• Time-to-event outcomes were estimated using the Kaplan-Meier method

Results: 

Demographics and clinical characteristics

• A total of 50 patients met the study criteria, including 36 patients (72.0%) eligible for teclistamab per USPI. Patient characteristics are presented in Table 1
• At Tec initiation, 40.0% of the overall cohort and 44.4% of the Tec-1 eligible subgroup were ages ≥75 years
• Among the overall and Tec-1 eligible cohorts, 46.0% and 38.9% had high-risk cytogenetics (t(4; 14); t (14; 16); t (14; 20) del17p, or gain/amp 1q21)), respectively

SUD

• A total of 38 patients (76.0%) in the overall cohort and 29 (80.6%) in the Tec-1 eligible subgroup were referred to another institution for inpatient SUD; the remaining patients (12 [24.0%] in the overall cohort and 7 [19.4%] in the Tec-1 eligible subgroup) completed SUD in the outpatient setting
• All patients referred to another institution for SUD returned to the community clinic within a median of 15 days after SUD completion